Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y12 ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.
Read the full article on WikipediaAcute coronary syndrome (myocardial infarction or unstable angina) Clinical criteria: The treatment must be in combination with aspirin, AND Patient must have percutaneous coronary intervention planned; OR Patient must have previously undergone percutaneous coronary intervention, AND Patient must not have a known history of either: (i) stroke, (ii) transient ischaemic attack, AND The treatment must be ceased if a percutaneous coronary intervention is not performed. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner who is continuing treatment with this medicine (of any strength) that was initiated by a medical practitioner as a PBS benefit. Population criteria: Patient must be at least 18 years of age. Patient must be treated with the recommended maintenance dose of prasugrel according to the TGA-approved Product Information.
“Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine (trade name Ticlid) and clopidogrel (trade name Plavix). These agents reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. Prasugrel inhibits platelet aggregation more rapidly, more consistently, and to a greater extent than clopidogrel. The TRITON-TIMI 38 study compared prasugrel with clopidogrel, and showed that prasugrel reduced rates of ischaemic events, but increased bleeding risk. Overall mortality rates were similar for each drug.”
“~7 h (range 2 h to 15 h)”
Working under the parallel aged-care framework? Aged-care equivalent →